Evaluation of nilotinib in advanced GIST previously treated with imatinib and sunitinib

Purpose Patients with advanced GIST following standard imatinib and sunitinib often have good performance status and need additional therapy. This study tested nilotinib, a second-generation tyrosine kinase inhibitor, in patients with advanced GIST refractory to standard therapies.